JP2007511570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511570A5 JP2007511570A5 JP2006540319A JP2006540319A JP2007511570A5 JP 2007511570 A5 JP2007511570 A5 JP 2007511570A5 JP 2006540319 A JP2006540319 A JP 2006540319A JP 2006540319 A JP2006540319 A JP 2006540319A JP 2007511570 A5 JP2007511570 A5 JP 2007511570A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxyphenyl
- phenyl
- moiety
- aminoisoquinoline
- quinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 -OCH 2 O- Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 241000711549 Hepacivirus C Species 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000018565 Hemochromatosis Diseases 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010051246 Photodermatosis Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000009251 neurologic dysfunction Effects 0.000 claims 2
- 208000015015 neurological dysfunction Diseases 0.000 claims 2
- 230000008845 photoaging Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- YCWJXRWJVLGYDO-UHFFFAOYSA-N 2-chloro-5-[1-(quinolin-6-ylamino)isoquinolin-5-yl]phenol Chemical compound C1=C(Cl)C(O)=CC(C=2C3=CC=NC(NC=4C=C5C=CC=NC5=CC=4)=C3C=CC=2)=C1 YCWJXRWJVLGYDO-UHFFFAOYSA-N 0.000 claims 1
- FDZCXCAEIMEZNY-UHFFFAOYSA-N 2-fluoro-4-[1-(quinolin-6-ylamino)isoquinolin-5-yl]phenol Chemical compound C1=C(F)C(O)=CC=C1C(C1=CC=N2)=CC=CC1=C2NC1=CC=C(N=CC=C2)C2=C1 FDZCXCAEIMEZNY-UHFFFAOYSA-N 0.000 claims 1
- OSQBRESWBRGMBK-UHFFFAOYSA-N 3-(1-aminoisoquinolin-5-yl)phenol Chemical compound C1=CC=C2C(N)=NC=CC2=C1C1=CC=CC(O)=C1 OSQBRESWBRGMBK-UHFFFAOYSA-N 0.000 claims 1
- CJYKWNWGSOLOHS-UHFFFAOYSA-N 3-(1-anilinoisoquinolin-5-yl)phenol Chemical compound OC1=CC=CC(C=2C3=CC=NC(NC=4C=CC=CC=4)=C3C=CC=2)=C1 CJYKWNWGSOLOHS-UHFFFAOYSA-N 0.000 claims 1
- JIIOVILZEUPVSW-UHFFFAOYSA-N 3-[1-(1,3-benzodioxol-5-ylamino)isoquinolin-5-yl]phenol Chemical compound OC1=CC=CC(C=2C3=CC=NC(NC=4C=C5OCOC5=CC=4)=C3C=CC=2)=C1 JIIOVILZEUPVSW-UHFFFAOYSA-N 0.000 claims 1
- KBFBCBPARLFWEY-UHFFFAOYSA-N 3-[1-(3-methoxyanilino)isoquinolin-5-yl]phenol Chemical compound COC1=CC=CC(NC=2C3=CC=CC(=C3C=CN=2)C=2C=C(O)C=CC=2)=C1 KBFBCBPARLFWEY-UHFFFAOYSA-N 0.000 claims 1
- YLIJQVWDNUBFNS-UHFFFAOYSA-N 3-[1-[3-(4-aminophenoxy)anilino]isoquinolin-5-yl]phenol Chemical compound C1=CC(N)=CC=C1OC1=CC=CC(NC=2C3=CC=CC(=C3C=CN=2)C=2C=C(O)C=CC=2)=C1 YLIJQVWDNUBFNS-UHFFFAOYSA-N 0.000 claims 1
- CRJJYCSHXGOVHI-UHFFFAOYSA-N 3-[1-[4-(trifluoromethyl)anilino]isoquinolin-5-yl]phenol Chemical compound OC1=CC=CC(C=2C3=CC=NC(NC=4C=CC(=CC=4)C(F)(F)F)=C3C=CC=2)=C1 CRJJYCSHXGOVHI-UHFFFAOYSA-N 0.000 claims 1
- LMEAKOZPBYGTEI-UHFFFAOYSA-N 3-[[5-(4-chloro-3-hydroxyphenyl)isoquinolin-1-yl]amino]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(NC=2C3=CC=CC(=C3C=CN=2)C=2C=C(O)C(Cl)=CC=2)=C1 LMEAKOZPBYGTEI-UHFFFAOYSA-N 0.000 claims 1
- PGPFEOOQPGIMNC-UHFFFAOYSA-N 4-[1-(quinolin-6-ylamino)isoquinolin-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C(C1=CC=N2)=CC=CC1=C2NC1=CC=C(N=CC=C2)C2=C1 PGPFEOOQPGIMNC-UHFFFAOYSA-N 0.000 claims 1
- MANBWPXVGMKSGN-UHFFFAOYSA-N 5-(1-aminoisoquinolin-5-yl)-1h-pyridin-2-one Chemical compound C1=CC=C2C(N)=NC=CC2=C1C=1C=CC(=O)NC=1 MANBWPXVGMKSGN-UHFFFAOYSA-N 0.000 claims 1
- SXMCQHZLBVWVEA-UHFFFAOYSA-N 5-(1h-indol-5-yl)isoquinolin-1-amine Chemical compound C1=C2NC=CC2=CC(C2=C3C=CN=C(C3=CC=C2)N)=C1 SXMCQHZLBVWVEA-UHFFFAOYSA-N 0.000 claims 1
- BHVKLMFYSQSTAA-UHFFFAOYSA-N 5-(3-methoxyphenyl)isoquinolin-1-amine Chemical compound COC1=CC=CC(C=2C3=CC=NC(N)=C3C=CC=2)=C1 BHVKLMFYSQSTAA-UHFFFAOYSA-N 0.000 claims 1
- RHIFJNPOCCMIBR-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)-n-quinolin-6-ylisoquinolin-1-amine Chemical compound C1=NC(OC)=CC=C1C(C1=CC=N2)=CC=CC1=C2NC1=CC=C(N=CC=C2)C2=C1 RHIFJNPOCCMIBR-UHFFFAOYSA-N 0.000 claims 1
- ROWZGFFRGAKDBG-UHFFFAOYSA-N 5-(6-methoxypyridin-3-yl)isoquinolin-1-amine Chemical compound C1=NC(OC)=CC=C1C1=CC=CC2=C(N)N=CC=C12 ROWZGFFRGAKDBG-UHFFFAOYSA-N 0.000 claims 1
- KLOHMIJHYQATRU-UHFFFAOYSA-N 5-[4-(methoxymethoxy)phenyl]-n-quinolin-6-ylisoquinolin-1-amine Chemical compound C1=CC(OCOC)=CC=C1C(C1=CC=N2)=CC=CC1=C2NC1=CC=C(N=CC=C2)C2=C1 KLOHMIJHYQATRU-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- KPXNHZYGRPBCST-UHFFFAOYSA-N [3-[[5-(3-hydroxyphenyl)isoquinolin-1-yl]amino]phenyl]urea Chemical compound NC(=O)NC1=CC=CC(NC=2C3=CC=CC(=C3C=CN=2)C=2C=C(O)C=CC=2)=C1 KPXNHZYGRPBCST-UHFFFAOYSA-N 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- DUCUMZZIKVYOCG-UHFFFAOYSA-N n-[3-[[5-(3-hydroxyphenyl)isoquinolin-1-yl]amino]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(NC=2C3=CC=CC(=C3C=CN=2)C=2C=C(O)C=CC=2)=C1 DUCUMZZIKVYOCG-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0326963.6A GB0326963D0 (en) | 2003-11-19 | 2003-11-19 | Compounds |
| PCT/EP2004/013072 WO2005049577A1 (en) | 2003-11-19 | 2004-11-17 | 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511570A JP2007511570A (ja) | 2007-05-10 |
| JP2007511570A5 true JP2007511570A5 (https=) | 2007-12-06 |
Family
ID=29764098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006540319A Pending JP2007511570A (ja) | 2003-11-19 | 2004-11-17 | 不適切なａｌｋ５に関連する疾患を治療するための１−アミノ−イソキノリン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070072901A1 (https=) |
| EP (1) | EP1689718A1 (https=) |
| JP (1) | JP2007511570A (https=) |
| GB (1) | GB0326963D0 (https=) |
| WO (1) | WO2005049577A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007005668A2 (en) * | 2005-06-30 | 2007-01-11 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| US7910595B2 (en) * | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| CN104520422B (zh) | 2012-05-30 | 2019-08-23 | 康奈尔大学 | 由人羊水来源的细胞生成功能性的和持久的内皮细胞 |
| EP3888640B1 (en) | 2013-06-05 | 2025-09-17 | Reverse Bioengineering, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| US10130625B2 (en) * | 2014-07-22 | 2018-11-20 | University Of Maryland, College Park | Linked diaryl compounds with anticancer properties and methods of using the same |
| CN108779435B (zh) | 2015-12-07 | 2022-05-03 | 再生疗法有限公司 | 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法 |
| CN114761405A (zh) * | 2019-11-29 | 2022-07-15 | 南京明德新药研发有限公司 | 抗hbv的1,7-萘啶类化合物 |
| US20250092031A1 (en) * | 2023-09-20 | 2025-03-20 | Momentum Therapeutics, Inc. | Ripk3 inhibitors and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030176454A1 (en) * | 2000-05-15 | 2003-09-18 | Akira Yamada | N-coating heterocyclic compounds |
| AU2002225730A1 (en) * | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
| WO2004065392A1 (en) * | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
-
2003
- 2003-11-19 GB GBGB0326963.6A patent/GB0326963D0/en not_active Ceased
-
2004
- 2004-11-17 EP EP04797975A patent/EP1689718A1/en not_active Withdrawn
- 2004-11-17 US US10/595,911 patent/US20070072901A1/en not_active Abandoned
- 2004-11-17 WO PCT/EP2004/013072 patent/WO2005049577A1/en not_active Ceased
- 2004-11-17 JP JP2006540319A patent/JP2007511570A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5236664B2 (ja) | 心血管疾患を予防および治療するための化合物 | |
| JP5298022B2 (ja) | 有機化合物 | |
| AU2006212761B2 (en) | Combination therapy | |
| JP2009503107A5 (https=) | ||
| JP2007511570A5 (https=) | ||
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| JP2010514716A5 (https=) | ||
| JP2007506749A5 (https=) | ||
| JP2002179594A (ja) | タチキニンｎｋ３受容体アンタゴニストとしてのキノリン誘導体 | |
| JP2004517049A5 (https=) | ||
| JP2010513304A5 (https=) | ||
| RU2008102968A (ru) | Производные изохинолина в качестве ингибиторов rho-киназы | |
| RU2009148304A (ru) | Модуляторы гидролазы амидов жирных кислот на основе гетероарилзамещенной мочевины | |
| JP2016506387A5 (https=) | ||
| KR0139626B1 (ko) | 강심제 | |
| KR20150090219A (ko) | Hbv 감염에 대항하여 항바이러스 물질로써 기능화된 벤자미드 유도체들 | |
| JP2014526501A5 (https=) | ||
| JP2013542937A5 (https=) | ||
| RU2004119438A (ru) | Производные бензотиазола | |
| JP2024524766A5 (https=) | ||
| JP2005512998A5 (https=) | ||
| RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
| RU2425029C2 (ru) | Соединение сульфонамида или его соль |